Business
Boston Scientific Caps Strong 2025 with Solid Q4, Meets Revenue Targets Amid Steady Growth
Boston Scientific (NYSE:BSX) reported fourth-quarter revenue of $5.29 billion, aligning with Wall Street forecasts and marking a 15.9% year-over-year increase. The medical device giant also posted adjusted earnings of $0.80 per share, slightly above consensus, while providing guidance in line with expectations for the coming quarter.